The same authors, in a previous study, targeted SIRP-α directly via a small molecule, Hu5F9-G4, reporting increased anti-tumor phagocytosis, with minimal activity against normal neural cells, both in in vitro and in patient-derived xenografts [33]. Here, SIRPA is linked to neoplasm.